Rivia

🔥Product & brand launch announcement Your clinical data can be a time-consuming mystery. Rivia Spark (a clinical AI assistant) changes that. In seconds, you can: 1. Understand adverse events and their potential causes. 2- Monitor patient visits without digging through spreadsheets. 3. Explore clinical response across endpoints over time. The results? Know better: Reliable, integrated data tailored to your questions — no waiting, no manual searching. Act better: Immediate insights empower confident decision-making. Stay on track: Informed trial decisions save time, reducing delays and risks.

🎄✨ From Our Team to Yours: Happy Festive Holidays! ✨🎄 As the year draws to a close, we want to take a moment to thank our valued clients, partners, and colleagues for an incredible journey together this year. Your trust, collaboration, and support mean the world to us! This holiday season, we wish you and your loved ones 💫 moments of joy and laughter 🎁 gifts of love and togetherness 🌟 and a new year filled with success and happiness. Let’s make 2025 even brighter - together! Happy Holidays and a Wonderful New Year!

Just got back from ESMO Geneva. And wow. Immuno-oncology research is truly inspiring. Here are 3 things that stood out: 1. T Cell Engineering & Functionality Engineering T cells to overcome immunosuppression and maintain functionality in the tumor microenvironment (TME) is critical for therapies like CAR-T and TCR-T. - Advancements in armored CAR-T cells (e.g., IL-12-secreting CAR-T) and CRISPR-based editing to enhance resistance to checkpoint blockade or metabolic suppression. - Efforts to improve trafficking and infiltration into solid tumors, which remain a major hurdle. - T cell exhaustion, such as modulating transcription factors like TOX or using checkpoint inhibitors in combination. 2. Vaccine-Based Immunotherapies - Oncolytic vaccines with checkpoint inhibitors or cytokine therapies (e.g., IL-2, IL-15) could overcome "second resistance." - anti-CD25 therapies: These target Tregs (regulatory T cells), which often suppress immune responses in the TME. Exciting progress into balancing immune activation without unleashing autoimmunity. - Use of mRNA vaccines in oncology (beyond COVID-19) and how they are influencing the immuno-oncology vaccine space. 3. Neoantigen Identification & Immune Profiling - Exome sequencing is a gold mine for neoantigen discovery - computational bio making big steps with AI to find immunogenic targets. - Circulating tumor DNA (ctDNA) can be used to detect those neoantigens (although detection in blood isn't possible yet) -  Several exciting neoantigen-based vaccines and TCR-T cell therapies are under development Overall, my 3 key areas to keep following: - Precision molecular tools shaping next-generation therapies. - Engineered immune cells overcoming tumor resistance. - Innovative vaccines transforming cancer care. Any thoughts on where cancer immunotherapies need to improve? Drop them in the comments.

👥 Please join us in welcoming Carolina Almeida and Zhentao Liu to our engineering and product team, we are super excited to have them with us, as we head into 2025! 🔒 Zhentao holds a Master’s in Cyber Security from EPFL and ETH Zürich. Before joining Rivia as a Software Engineer, Zhentao gained valuable experience through internships at Logitech, ELCA Group, and Tune Insight, working on projects in full-stack development, AI , and security. Zhentao is a Chinese Go player who is actively competing in Go tournaments across Europe. 🔧 Carolina holds a Master's degree in Biomedical Engineering from Universidade de Aveiro Portugal and brings valuable experience in both tech startups and data science. She has developed innovative wearable technologies and led a small-scale clinical trial, earning academic recognition for her work. Outside of work, she's a music lover and avid vinyl collector, with a deep appreciation for the artistry and history behind the records she collects. Welcome to the team Zhentao Liu and Carolina Almeida, looking forward to what we will achieve together 🔥 #team #growth

🌟 Last week the team gathered at the heights of Zürich to plan for 2025. Uetliberg was the perfect outlook as we worked on how we want to grow in the coming year ⛰️ During our team offsite, we focused on collective growth and acceleration. What does this mean: 1️⃣ We worked as pairs and groups on perfecting our product pitch, USP, and use cases for different client personas (not only pitching to scientists and lab experts but also our children and grandparents) - this was great fun and imaginative! 2️⃣ We worked in pairs and as a team to understand our individual and team soft and hard competencies. Using a range of competencies, we learned more about ourselves and each other, and how we can work together / communicate effectively, as the team grows. 3️⃣ Together we aimed to understand how we evolved as a company. Growing from 3 to 12 employees in a few months brought cultural changes. As a team, we defined our Guiding Principles, which allows us to better understand our cultural environment, how we collaborate, and how / who we want to bring into the tea in 2025. 👉 We had many individual and team outcomes and learnings and the biggest outcome from the offsite was one of a combined mission, we're all in this, we're invested and in it to win it - let's go team 🤩 #teamgrowth #teamoffsite #letsgo

🎥 Hear from Blanky at Alentis Therapeutics in our latest testimonial video 👇 With Rivia, you won’t just know better—you’ll act better! 🔥 Introducing Rivia 2.0 The AI-driven, unified trial data platform that transforms how clinical trials are run: • Integrate any data source in days (not months). • Access a single source of truth across all vendors and programs. • Customize your workflows and get answers faster with AI-powered assistants. Why it matters: • Eliminate data fragmentation and simplify trial operations. • Detect and address issues early—before they become roadblocks. • Improve data integrity to reduce costs and accelerate timelines. #therapeuticinnovation #clinicaltrialsimprovements #dataclarity

ℹ️ Biotechs face numerous challenges when running clinical trials, including difficulties in analyzing data from multiple sources, fragmented data, and reliance on service providers. These challenges can result in inefficiencies, delays, and difficulty making informed decisions about trial conduct. 👉 Rivia helps gain insights across clinical programs and automates data management. Find out more here: https://buff.ly/3zWMd8w #biotechs #clinicalprograms #clinicaldelays

🫕 Tis the season to eat #fondue. In the last 2 months, our team has grown from 4 employees to 9 🤯 with 3 new employees yet to start in the coming weeks! To celebrate our growth and welcome our new joiners, we did the most appropriate thing to do when winter arrives in Zürich - fondue together 🤤 💗 Here's to more team events as we continue to grow and welcome new talent. #teamgrowth #growth #teamevent

👉 Erik Scalfaro will be in Boston next week attending the Precision in Clinical Trials Oncology Summit. This event is a pivotal gathering for industry professionals, offering a chance to explore innovative solutions and advancements in clinical trial methodologies. We are keen to engage with fellow experts and share insights on enhancing the efficiency and effectiveness of clinical trials. 👥 If you are interested in a direct meeting with Erik while he's in Boston, please reach out. We look forward to fostering valuable connections. #ClinicalInnovation #OncologySummit #Boston Precision Evolution Global

🎉 We are thrilled to announce the expansion of our Engineering team with the addition of Barnabás Südy and Loris Giulivi in November. They both bring a wealth of experience and extensive knowledge in engineering and AI to our group. 🔧 Barnabás joins us with 15 years of engineering expertise, having come from Beekeeper, where he led the development of various features and components, including backend systems, mobile apps, and web platforms. 🎓 Loris recently completed his PhD at Politecnico di Milano, focusing on Explainable AI, and he wrapped up an internship at Amazon, where he worked on multi-modal textual and visual representation learning for attribute-based recommendations in extensive catalogs. Join us in giving them a warm welcome to the team! 💖 #teamexpansion #teamsuccess #warmwelcome